The U.S. Food and Drug Administration approved AstraZeneca PLC's Lokelma to treat hyperkalemia in adults.
Hyperkalemia is a disorder characterized by high levels of potassium in the blood.
The approval for Lokelma, a highly selective, oral potassium-removing agent, is backed by three late-stage clinical studies. Data from one trial showed that 92% of patients on the drug achieved normal potassium levels within 48 hours from the start of the study.
In March, the European Commission approved Lokelma for the treatment of the same disease in adults.